Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.63 |
| ▸ | DPP8 | Q6V1X1 | 8/20 | 0.55 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL197391 | 1.00 | DPP4 (0.63) | DPP4DPP8DPP7 | |
| SCHEMBL2976242 | 0.97 | DPP4 (0.59) | DPP4DPP8DPP7 | |
| SCHEMBL666248 | 0.97 | DPP4 (0.59) | DPP4DPP8DPP7 | |
| SCHEMBL1436263 | 0.91 | DPP4 (0.55) | DPP4DPP8DPP7 | |
| SCHEMBL666999 | 0.91 | DPP4 (0.55) | DPP4DPP8DPP7 | |
| SCHEMBL4594315 | 0.91 | DPP4 (0.54) | DPP4DPP8DPP7 | |
| SCHEMBL665830 | 0.91 | DPP4 (0.54) | DPP4DPP8DPP7 | |
| SCHEMBL1436492 | 0.91 | DPP4 (0.55) | DPP4 | |
| SCHEMBL667336 | 0.91 | DPP4 (0.55) | DPP4 | |
| SCHEMBL4636425 | 0.90 | DPP4 (0.58) | DPP4DPP8DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014074668-A1 | MODULATORS OF GPR119 AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2014-05-15 | — | — | WO | claimed |
| WO-2012145361-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2012-10-26 | — | — | WO | claimed |
| WO-2011005929-A1 | PIPERIDINE DERIVATIVE AND ITS USE FOR THE TREATMENT OF DIABETS AND OBESITY | ARENA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | claimed |
| JP-2008534470-A | — | — | 2008-08-28 | — | — | JP | claimed |
| EP-1917001-A2 | PHARMACEUTICAL COMPOSITION COMPRISING A DPP-IV INHIBITOR | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-07 | — | — | EP | claimed |
| EP-1888571-A2 | NEW SALT AND POLYMORPHS OF A DPP-IV INHIBITOR | F. Hoffmann-Roche AG (CH) | 2008-02-20 | — | — | EP | claimed |
| WO-2007017423-A2 | PHARMACEUTICAL COMPOSITION COMPRISING A DPP-IV INHIBITOR | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-15 | — | — | WO | claimed |
| WO-2006100181-A2 | NEW SALT AND POLYMORPHS OF A DPP-IV INHIBITOR | F. HOFFMANN-LA ROCHE AG (CH) | 2006-09-28 | — | — | WO | claimed |
| US-20060217428-A1 | Salt and polymorphs of a DPPIV inhibitor | HOFFMANN-LA ROCHE INC. | 2006-09-28 | — | — | US | claimed |
| EP-1441719-A1 | N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-04 | — | — | EP | claimed |
| WO-2003037327-A1 | N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | F. HOFFMANN-LA-ROCHE AG (CH) | 2003-05-08 | — | — | WO | claimed |
| US-20260001873-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2026-01-01 | — | — | US | disclosed |
| US-12384772-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. (DE) | 2025-08-12 | — | — | US | disclosed |
| CN-117024352-A | Novel inhibitors | 维沃里翁治疗股份有限公司 | 2023-11-10 | — | — | CN | disclosed |
| US-20220274977-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2022-09-01 | — | — | US | disclosed |
| WO-2007017423-A2 | PHARMACEUTICAL COMPOSITION COMPRISING A DPP-IV INHIBITOR | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-15 | — | — | WO | disclosed |
| WO-2006100181-A2 | NEW SALT AND POLYMORPHS OF A DPP-IV INHIBITOR | F. HOFFMANN-LA ROCHE AG (CH) | 2006-09-28 | — | — | WO | disclosed |
| US-20060217428-A1 | Salt and polymorphs of a DPPIV inhibitor | HOFFMANN-LA ROCHE INC. | 2006-09-28 | — | — | US | disclosed |
| EP-1441719-A1 | N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003037327-A1 | N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | F. HOFFMANN-LA-ROCHE AG (CH) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001873-A1 | NOVEL INHIBITORS | GLS, GLS2, SULT1E1 | DPP4 798/4885DPP8 521/4885DPP7 573/4885 |
| US-12384772-B2 | Inhibitors | GLS, QPCT, GLS2 | DPP4 911/4885DPP8 697/4885DPP7 491/4885 |
| US-20220274977-A1 | NOVEL INHIBITORS | GLUL, GLS, QPCT | DPP4 747/4885DPP8 825/4885DPP7 581/4885 |
| US-20060217428-A1 | Salt and polymorphs of a DPPIV inhibitor | DPP4, DPP3, DPP9 | DPP4 1/4885DPP8 6/4885DPP7 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.